Alector Shares Jump On $2.2B Immuno-Neurology Development Pact With GSK

Alector Inc ALEC and GlaxoSmithKline plc GSK have announced a global collaboration for the development and commercialization of two monoclonal antibodies designed to elevate progranulin (PGRN) levels.
PGRN is a crucial regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders.
Alector will receive $700 million in upfront payments and is eligible to receive up to an additional $1.5 billion in milestone payments.
Alector will lead the global development of AL001 and AL101 through Phase 2 proof-of-concept.
After that, Alector and GSK will share development responsibilities for all late-stage clinical studies for AL001 and AL101.
All costs for global development will be divided between the two companies, and will be jointly responsible for commercialization in the U.S. and will share profits and losses.
Alector will lead commercial efforts associated with AL001 in orphan indications, and GSK will lead the commercialization of AL101 in Alzheimer's and Parkinson's disease.
Outside the U.S., GSK will be responsible for the commercialization of AL001 & AL101, and Alector will be eligible for tiered royalties.
Price Action: ALEC shares are up 39% at $31.15 during the premarket session on the last check Friday.